Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO ‐2b/3
International Journal of Dermatology · 2026
DOI: 10.1111/ijd.70035 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Dermatology, 2026. Verfasst von Ernest H Law und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer, Inc., New York, New York, USA. Hauptthemen laut MEDLINE: Alopecia Areata. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Background
Patients with alopecia areata (AA) in ALLEGRO‐2b/3 (NCT03732807) had clinically significant hair regrowth and patient‐reported improvements with ritlecitinib versus placebo, but patient‐reported improvements in AA Patient Priority Outcomes (AAPPO) emotional symptoms (ES) or activity limitations (AL) were not observed during the 24‐week placebo‐controlled phase. This study compared AAPPO scores between the 50‐mg ritlecitinib maintenance dose (+/− 200‐mg 4‐week loading dose) and subtherapeutic 10‐mg ritlecitinib through Week 48 of ALLEGRO‐2b/3.
Methods
Least squares mean (LSM) changes from baseline (CFBs) in domain scores were estimated for the full analysis population and for participants with baseline domain scores ≥ 1. Item‐level responses (scores < 2) were evaluated for participants with baseline item scores ≥ 2, since lower baseline item scores (measured on 5‐point response scales; range, 0–4) indicated less frequent/severe impacts from hair loss.
Results
There were 325 participants (200/50‐mg [ n = 132] and 50‐mg [ n = 130], combined and as subgroups; 10‐mg [ n = 63]). LSM CFBs in ES and AL domain scores generally improved through Week 48 for all 50‐mg groups, with significant differences versus 10‐mg starting at Week 34 for ES and Week 40 for AL. The proportion of responders for all ES and AL items generally increased through Week 48 for all 50‐mg groups. The largest improvements versus 10‐mg were for ES items 5 and 6 (self‐consciousness and embarrassment) and AL item 11 (interactions with others).
Conclusions
ALLEGRO‐2b/3 participants reported greater improvements in ES and AL due to hair loss by Week 48 with the 50‐mg ritlecitinib maintenance dose (+/− 200‐mg loading dose) versus subtherapeutic 10‐mg ritlecitinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pfizer, Inc., New York, New York, USA.
- RTI Health Solutions, North Carolina, USA.
- Department of Dermatology, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Dermatology, Yale University, New Haven, Connecticut, USA.
- Sinclair Dermatology, East Melbourne, Victoria, Australia.
- Department of Dermatology, University of California, Irvine, California, USA.
ORCID-Profile: Ernest H Law, Bintu Sherif, Arash Mostaghimi, Brett King, Rodney Sinclair, Natasha Mesinkovska, Kent A Hanson, Dane Korver, Costel Chirila
Förderung
- Pfizer
Zitieren
APA
Law, E. H., Sherif, B., Mostaghimi, A., King, B., Sinclair, R., Mesinkovska, N., Hanson, K. A., Korver, D., & Chirila, C. (2026). Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO ‐2b/3. International Journal of Dermatology. https://doi.org/10.1111/ijd.70035
Vancouver
Law EH, Sherif B, Mostaghimi A, King B, Sinclair R, Mesinkovska N, et al. Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO ‐2b/3. International Journal of Dermatology. 2026. doi:10.1111/ijd.70035
BibTeX
@article{Law2026,
author = {Law, Ernest H and Sherif, Bintu and Mostaghimi, Arash and King, Brett and Sinclair, Rodney and Mesinkovska, Natasha and Hanson, Kent A and Korver, Dane and Chirila, Costel},
title = {Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO ‐2b/3},
journal = {International Journal of Dermatology},
year = {2026},
doi = {10.1111/ijd.70035}
}
EUVIMED